Staying on hormone therapy for early breast cancer
Part of Cancer, Skin clinical trials.
This study looks at how well patients take their hormone-lowering pills (aromatase inhibitors, with or without abemaciclib) for early-stage breast cancer. It aims to understand adherence patterns and help improve support for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female
- You have early-stage, hormone receptor-positive, HER2-negative breast cancer
- You are currently taking an aromatase inhibitor (letrozole, anastrozole, or exemestane), with or without abemaciclib, for no more than 18 months
- You are being treated at the Institute of Oncology Ljubljana
- You have mandatory health insurance in Slovenia
- You understand Slovenian and agree to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at how well people stick to a treatment plan that combines hormone therapy with a pill called a CDK4/6 inhibitor after surgery for early-stage breast cancer. The goal is to learn more about adherence so doctors can help patients stay on track.
This trial checks how well people stick to their prescribed ribociclib (Kisqali) plus aromatase inhibitor treatment for early-stage, hormone-receptor-positive, HER2-negative breast cancer, and monitors for side effects. It focuses on making sure patients are safe and supported while taking their medication.
This study looks at whether supporting patients helps them stick to their prescribed oral breast cancer treatment (abemaciclib and hormone therapy). If you're already taking this combination for early-stage breast cancer, the study team may provide extra guidance to help you stay on track.
This study follows women taking abemaciclib (a targeted cancer drug) for early-stage hormone-receptor-positive breast cancer to understand how the treatment affects their quality of life and health outcomes. The goal is to improve care for people in this situation.
This study looks at the effectiveness of the drugs abemaciclib and olaparib plus hormone therapy for people with high-risk, hormone receptor-positive, HER2-negative early breast cancer. It aims to understand how well these treatments work in real-world settings.
This trial tests whether adding abemaciclib to standard hormone (endocrine) therapy can improve outcomes for certain types of advanced breast cancer. It also uses a phone app to help you and the team track side effects so problems can be caught early.
Hear when a new Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.